Shots:

• Sema4 will acquire GeneDx for a total consideration of ~$623M including $150M up front in cash, 80.0M shares in Sema4's common stock (~$473M as total upfront), ~$150M revenue-based milestones for a next 2 yrs. The combined company is expected to provide $350M in pro forma 2022 revenue
• Sema4 also entered into agreements for a $200M private placement in Class A common stock at $4.00/share from Pfizer & institutional investors. The transaction is expected to close in Q2’22,
• The acquisition strengthens Sema4’s AI-driven genomic & clinical data intelligence platform & add GeneDx’s database of clinical exomes & annotated phenotypes to Sema4’s platform to enable precision medicine to patients

Ref: Sem4 | Image: HIT Consultant